Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Announces Initiation of Enrollment in Second Cohort of CTP-543 Phase 2a Trial for Alopecia Areata
Phase 2a Trial On Track to Complete in Second Half of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 12, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543.
View HTML
Toggle Summary FDA Grants Fast Track Designation to Concert Pharmaceuticals' CTP-543 for the Treatment of Alopecia Areata
CTP-543 is a Novel JAK Inhibitor in Phase 2 for Alopecia Areata as Potential First-in-Class Treatment LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543, a
View HTML
Toggle Summary Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has decided not to grant the Company's Post Grant Review (PGR) petition challenging the validity of U.S. Patent No.
View HTML
Toggle Summary Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018 . Mr. Becker is a seasoned financial executive with more than 15 years of experience in the biotechnology industry.
View HTML
Toggle Summary Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 18, 2017 .
View HTML
Toggle Summary Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017. "This is an exciting time for our deuterium-based chemistry as we continue to demonstrate our
View HTML
Toggle Summary Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial
CTP-543 is Being Evaluated in Moderate-to-Severe Alopecia Areata Phase 2a Trial On Track to Complete in Second Half of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed enrollment of the first cohort of its Phase 2a trial
View HTML
Toggle Summary Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences
LEXINGTON, Mass.--( BUSINESS WIRE )-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has denied Incyte's petition to institute inter partes review (IPR) of U.S. Patent No.
View HTML
Toggle Summary Concert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that it will present a corporate overview at the Wells Fargo 2017 Healthcare Conference on Thursday, September 7, 2017 , at 11:10 a.m. EDT at the Westin Waterfront in Boston .
View HTML